NASDAQ: GOSSGossamer Bio Inc Stock
$0.84+0.01 (+1.2%)
Updated Apr 17, 2025
GOSS Price
$0.84
Fair Value Price
N/A
Market Cap
$191.55M
52 Week Low
$0.50
52 Week High
$1.55
P/E
-3.37x
P/B
6.49x
P/S
1.78x
PEG
N/A
Dividend Yield
N/A
Revenue
$114.70M
Earnings
-$56.53M
Gross Margin
100%
Operating Margin
-38.46%
Profit Margin
-49.3%
Debt to Equity
9.69
Operating Cash Flow
-$3M
Beta
1.36
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
GOSS Overview
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GOSS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GOSS
Ranked#63 of 463
Ranked#63 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important GOSS news, forecast changes, insider trades & much more!
GOSS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GOSS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GOSS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GOSS is poor value based on its book value relative to its share price (6.49x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
GOSS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GOSS due diligence checks available for Premium users.
Valuation
GOSS fair value
Fair Value of GOSS stock based on Discounted Cash Flow (DCF)
Price
$0.84
Fair Value
$4.04
Undervalued by
79.21%
GOSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GOSS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.37x
Industry
-177.72x
Market
27.98x
GOSS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.49x
Industry
4.05x
GOSS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GOSS's financial health
Profit margin
Revenue
$9.4M
Net Income
-$33.0M
Profit Margin
-352.2%
GOSS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GOSS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$315.3M
Liabilities
$285.8M
Debt to equity
9.69
GOSS's short-term assets ($309.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GOSS's short-term assets ($309.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GOSS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GOSS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$35.5M
Investing
$53.2M
Financing
$0.0
GOSS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GOSS vs Biotech Stocks
Gossamer Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.